Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: Roles for dual oxidase 2- and caspase-dependent pathways

Journal of Immunology

Volumn 186, Issue 2, 2011, Pages 1180-1188

  Yu, Man ^a   Lam, Jonathan ^a   Rada, Balázs ^b   Leto, Thomas L ^b   Levine, Stewart J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CASPASE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; DOUBLE STRANDED RNA; OXIDASE 2; OXIDOREDUCTASE; POLYINOSINIC POLYCYTIDYLIC ACID; REACTIVE OXYGEN METABOLITE; RECEPTOR INTERACTING PROTEIN 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; EPITHELIUM CELL; EXOSOME; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; RESPIRATORY EPITHELIUM; RNA INTERFERENCE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; APOPTOSIS; BRONCHI; CASPASES; CELL LINE; EXTRACELLULAR SPACE; HUMANS; MOLECULAR WEIGHT; NADPH OXIDASE; NUCLEAR PORE COMPLEX PROTEINS; POLY I-C; REACTIVE OXYGEN SPECIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RESPIRATORY MUCOSA; RNA, DOUBLE-STRANDED; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY; TOLL-LIKE RECEPTOR 3;

EID: 79251549181     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001499     Document Type: Article

References (69)

1. Beutler, B., and A. Cerami. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518.
2. Beyaert, R., and W. Fiers. 1994. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett. 340: 9-16.
3. Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
4. Rothe, J., G. Gehr, H. Loetscher, and W. Lesslauer. 1992. Tumor necrosis factor receptors - structure and function. Immunol. Res. 11: 81-90.
5. Vilcek, J., and T. H. Lee. 1991. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266: 7313-7316.
6. Wajant, H., K. Pfizenmaier, and P. Scheurich. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10: 45-65.
7. Tracey, K. J., and A. Cerami. 1993. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9: 317-343.
8. Chen, G., and D. V. Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635.
9. Booth, A. D., D. R. Jayne, R. K. Kharbanda, C. M. McEniery, I. S. Mackenzie, J. Brown, and I. B. Wilkinson. 2004. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109: 1718-1723.
10. Olsen, N. J., and C. M. Stein. 2004. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350: 2167-2179.
11. Hürlimann, D., A. Forster, G. Noll, F. Enseleit, R. Chenevard, O. Distler, M. Béchir, L. E. Spieker, M. Neidhart, B. A. Michel, et al. 2002. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: 2184-2187.
12. Schinzari, F., A. Armuzzi, B. De Pascalis, N. Mores, M. Tesauro, D. Melina, and C. Cardillo. 2008. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin. Pharmacol. Ther. 83: 70-76.
13. Brightling, C., M. Berry, and Y. Amrani. 2008. Targeting TNF-alpha: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol. 121: 5-10, quiz 11-12.
14. Chung, K. F. 2006. Cytokines as targets in chronic obstructive pulmonary disease. Curr. Drug Targets 7: 675-681.
15. Baughman, R. P., and M. Iannuzzi. 2003. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431.
16. Smith, C. A., T. Farrah, and R. G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962.
17. Devin, A., A. Cook, Y. Lin, Y. Rodriguez, M. Kelliher, and Z. Liu. 2000. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 12: 419-429.
18. Hsu, H., J. Huang, H. B. Shu, V. Baichwal, and D. V. Goeddel. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387-396.
19. Hsu, H., H. B. Shu, M. G. Pan, and D. V. Goeddel. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308.
20. Hsu, H., J. Xiong, and D. V. Goeddel. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81: 495-504.
21. Engelmann, H., D. Aderka, M. Rubinstein, D. Rotman, and D. Wallach. 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264: 11974-11980.
22. Hawari, F. I., F. N. Rouhani, X. Cui, Z. X. Yu, C. Buckley, M. Kaler, and S. J. Levine. 2004. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc. Natl. Acad. Sci. USA 101: 1297-1302.
23. Seckinger, P., S. Isaaz, and J. M. Dayer. 1989. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J. Biol. Chem. 264: 11966-11973.
24. Schall, T. J., M. Lewis, K. J. Koller, A. Lee, G. C. Rice, G. H. Wong, T. Gatanaga, G. A. Granger, R. Lentz, H. Raab, et al. 1990. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361-370.
25. Olsson, I., M. Lantz, E. Nilsson, C. Peetre, H. Thysell, A. Grubb, and G. Adolf. 1989. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. J. Haematol. 42: 270-275.
26. Reddy, P., J. L. Slack, R. Davis, D. P. Cerretti, C. J. Kozlosky, R. A. Blanton, D. Shows, J. J. Peschon, and R. A. Black. 2000. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J. Biol. Chem. 275: 14608-14614.
27. Gómez, M. I., M. O. Seaghdha, and A. S. Prince. 2007. Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J. 26: 701-709.
28. Islam, A., B. Adamik, F. I. Hawari, G. Ma, F. N. Rouhani, J. Zhang, and S. J. Levine. 2006. Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. J. Biol. Chem. 281: 6860-6873.
29. Cui, X., F. Hawari, S. Alsaaty, M. Lawrence, C. A. Combs, W. Geng, F. N. Rouhani, D. Miskinis, and S. J. Levine. 2002. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J. Clin. Invest. 110: 515-526.
30. Islam, A., X. Shen, T. Hiroi, J. Moss, M. Vaughan, and S. J. Levine. 2007. The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles. J. Biol. Chem. 282: 9591-9599.
31. Lantz, M., U. Gullberg, E. Nilsson, and I. Olsson. 1990. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J. Clin. Invest. 86: 1396-1402.
32. Levine, S. J., B. Adamik, F. I. Hawari, A. Islam, Z. X. Yu, D. W. Liao, J. Zhang, X. Cui, and F. N. Rouhani. 2005. Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L233-L243.
33. Levine, S. J., C. Logun, D. P. Chopra, J. S. Rhim, and J. H. Shelhamer. 1996. Protein kinase C, interleukin-1 beta, and corticosteroids regulate shedding of the type I, 55 kDa TNF receptor from human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 14: 254-261.
34. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4: 499-511.
35. O'Neill, L. A., K. A. Fitzgerald, and A. G. Bowie. 2003. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 24: 286-290.
36. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
37. McGettrick, A. F., and L. A. O'Neill. 2004. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol. 41: 577-582.
38. Theofilopoulos, A. N., R. Baccala, B. Beutler, and D. H. Kono. 2005. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23: 307-336.
39. Barton, G. M., and R. Medzhitov. 2003. Toll-like receptor signaling pathways. Science 300: 1524-1525.
40. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
41. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
42. Ryan, K. A., M. F. Smith, Jr., M. K. Sanders, and P. B. Ernst. 2004. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infect. Immun. 72: 2123-2130.
43. Nakahira, K., H. P. Kim, X. H. Geng, A. Nakao, X. Wang, N. Murase, P. F. Drain, X. Wang, M. Sasidhar, E. G. Nabel, et al. 2006. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J. Exp. Med. 203: 2377-2389.
44. Forteza, R., M. Salathe, F. Miot, R. Forteza, and G. E. Conner. 2005. Regulated hydrogen peroxide production by Duox in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 32: 462-469.
45. Geiszt, M., J. Witta, J. Baffi, K. Lekstrom, and T. L. Leto. 2003. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 17: 1502-1504.
46. Salaun, B., I. Coste, M. C. Rissoan, S. J. Lebecque, and T. Renno. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176: 4894-4901.
47. Myers, T. J., L. H. Brennaman, M. Stevenson, S. Higashiyama, W. E. Russell, D. C. Lee, and S. W. Sunnarborg. 2009. Mitochondrial reactive oxygen species mediate GPCR-induced TACE/ADAM17-dependent transforming growth factor-alpha shedding. Mol. Biol. Cell 20: 5236-5249.
48. Xanthoulea, S., M. Pasparakis, S. Kousteni, C. Brakebusch, D.Wallach, J. Bauer, H. Lassmann, and G. Kollias. 2004. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 200: 367-376.
49. Gómez, M. I., A. Lee, B. Reddy, A. Muir, G. Soong, A. Pitt, A. Cheung, and A. Prince. 2004. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 10: 842-848.
50. Cusson-Hermance, N., S. Khurana, T. H. Lee, K. A. Fitzgerald, and M. A. Kelliher. 2005. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-kappaB activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem. 280: 36560-36566.
51. Oshiumi, H., M. Matsumoto, K. Funami, T. Akazawa, and T. Seya. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol. 4: 161-167.
52. Jiang, Z., M. Zamanian-Daryoush, H. Nie, A. M. Silva, B. R. Williams, and X. Li. 2003. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem. 278: 16713-16719.
53. Park, S., D. B. Ramnarain, K. J. Hatanpaa, B. E. Mickey, D. Saha, R. Paulmurugan, C. J. Madden, P. S. Wright, S. Bhai, M. A. Ali, et al. 2008. The death domain-containing kinase RIP1 regulates p27(Kip1) levels through the PI3K-Akt-forkhead pathway. EMBO Rep. 9: 766-773.
54. Dong, L. W., X. N. Kong, H. X. Yan, L. X. Yu, L. Chen, W. Yang, Q. Liu, D. D. Huang, M. C. Wu, and H. Y. Wang. 2008. Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. Mol. Immunol. 45: 3025-3035.
55. Xu, Y., S. O. Kim, Y. Li, and J. Han. 2006. Autophagy contributes to caspase-independent macrophage cell death. J. Biol. Chem. 281: 19179-19187.
56. Rada, B., and T. L. Leto. 2010. Characterization of hydrogen peroxide production by Duox in bronchial epithelial cells exposed to Pseudomonas aeruginosa. FEBS Lett. 584: 917-922.
57. Zhang, Z., P. Oliver, J. R. Lancaster, Jr., P. O. Schwarzenberger, M. S. Joshi, J. Cork, and J. K. Kolls. 2001. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J. 15: 303-305.
58. Koff, J. L., M. X. Shao, I. F. Ueki, and J. A. Nadel. 2008. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L1068-L1075.
59. Rada, B., K. Lekstrom, S. Damian, C. Dupuy, and T. L. Leto. 2008. The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J. Immunol. 181: 4883-4893.
60. Harper, R. W., C. Xu, J. P. Eiserich, Y. Chen, C. Y. Kao, P. Thai, H. Setiadi, and R. Wu. 2005. Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett. 579: 4911-4917.
61. Danial, N. N., and S. J. Korsmeyer. 2004. Cell death: critical control points. Cell 116: 205-219.
62. Laplanche, A., L. Alzieu, T. Delozier, J. Berlie, C. Veyret, P. Fargeot, M. Luboinski, and J. Lacour. 2000. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 64: 189-191.
63. Madge, L. A., M. R. Sierra-Honigmann, and J. S. Pober. 1999. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1). A nonpharmacological explanation for inhibition of TNF-mediated activation. J. Biol. Chem. 274: 13643-13649.
64. Lin, Y., A. Devin, Y. Rodriguez, and Z. G. Liu. 1999. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 13: 2514-2526.
65. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
66. Häcker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang, M. P. Kamps, E. Raz, H. Wagner, G. Häcker, et al. 2006. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204-207.
67. Keating, S. E., G. M. Maloney, E. M. Moran, and A. G. Bowie. 2007. IRAK-2 participates in multiple toll-like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. J. Biol. Chem. 282: 33435-33443.
68. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar, A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208-211.
69. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300: 1148-1151.